Madrigal Pharma Secures $500M Credit Facility
Ticker: MDGL · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1157601
Sentiment: neutral
Topics: credit-facility, financing, corporate-action
Related Tickers: MDGL
TL;DR
Madrigal just locked in a $500M credit line from JPM, maturing in 2029. Good for flexibility.
AI Summary
Madrigal Pharmaceuticals, Inc. announced on March 27, 2024, that it has entered into a new credit agreement with JPMorgan Chase Bank, N.A. This agreement provides a $500 million revolving credit facility, which Madrigal can use for general corporate purposes. The facility matures on March 27, 2029.
Why It Matters
This new credit facility provides Madrigal Pharmaceuticals with significant financial flexibility for future growth and operational needs, potentially supporting research, development, or strategic initiatives.
Risk Assessment
Risk Level: low — The filing is a standard credit agreement announcement, indicating routine financial operations rather than a significant event that would inherently increase risk.
Key Numbers
- $500M — Revolving Credit Facility (Provides financial flexibility for general corporate purposes.)
- 5 years — Maturity Term (The credit facility is available until March 27, 2029.)
Key Players & Entities
- Madrigal Pharmaceuticals, Inc. (company) — Registrant
- JPMorgan Chase Bank, N.A. (company) — Lender
- $500 million (dollar_amount) — Revolving credit facility amount
- March 27, 2024 (date) — Date of credit agreement
- March 27, 2029 (date) — Maturity date of credit facility
FAQ
What is the purpose of the new credit agreement?
The credit agreement provides Madrigal Pharmaceuticals with a $500 million revolving credit facility that can be used for general corporate purposes.
Who is the lender in this new credit agreement?
JPMorgan Chase Bank, N.A. is the lender under the new credit agreement.
When does the new credit facility mature?
The new credit facility matures on March 27, 2029.
What is the total amount of the revolving credit facility?
The total amount of the revolving credit facility is $500 million.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is March 27, 2024.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-02 16:31:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ
- $260.00 — public offering price for the Shares of $260.00 per share, less underwriting discounts
- $86.0 m — ompany, is expected to be approximately $86.0 million, or approximately $660.0 million
- $660.0 million — imately $86.0 million, or approximately $660.0 million in aggregate for the Offering including
Filing Documents
- d818318d8k.htm (8-K) — 23KB
- 0001193125-24-084797.txt ( ) — 146KB
- mdgl-20240327.xsd (EX-101.SCH) — 3KB
- mdgl-20240327_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240327_pre.xml (EX-101.PRE) — 11KB
- d818318d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Madrigal Pharmaceuticals, Inc. (the Registrant) Date: April 2, 2024 By: /s/ Mardi C. Dier Mardi C. Dier Senior Vice President and Chief Financial Officer